| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| CUE | CUE | Shares | USD | XNCM |
| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| CUE | CUE | Shares | USD | XNCM |
Cue Biopharma, Inc. is a biotechnology company focused on developing precision immuno-engineered therapies for allergic and autoimmune diseases. Its lead product, CUE-221, is an anti-IgE antibody in Phase 2 development aimed at treating IgE-mediated allergic diseases. The company also utilizes its Immuno-STAT® platform to create therapies that selectively target disease-specific T cells for autoimmune conditions, with CUE-401, a bifunctional IL-2 and TGF-β program, advancing toward Phase 1 development. Cue Biopharma operates primarily in the United States.
No recent RNS announcements for CUE across CUE.
No recent RNS announcements for CUE across CUE.